Molecular Pathways of Protein Misfolding: How Structural Failure Drives Neurodegenerative Disorders

Sujit Pappala

Introduction

Proteins serve as the machinery that allow cells to grow, communicate, and carry out essential biochemical reactions. Every protein starts out as a simple chain of amino acids, but then fold into specific three-dimensional shapes before it can function. These unique shapes determine how the protein interacts with other molecules, what reactions it can catalyze, and how it contributes to the overall health of the cell. Even small deviations in the new protein structure can prevent a protein from working correctly or even cause it to be harmful for the cell. To help proteins reach their correct shape without such deviations, cells utilize molecular chaperones, which act as guides for the protein during the folding process. Cells also maintain control systems that monitor newly formed proteins and remove those that fail to fold properly. Together, these mechanisms form a larger proteostasis network that ensures the stability and functionality of the cell. The folding errors begin to occur, misfolded proteins can start to accumulate. This leads the proteins to lose the essential function that they are intended for, which causes them to negatively interfere in other cellular processes. After some time, these misfolded proteins can cause disruptions like damaging cell membranes, inhibit communication between neurons, and can contribute to chronic cellular stress that can lead to apoptosis, the self destruction of the cell. Neurons are especially sensitive to protein misfolding because they heavily depend on precise protein function and cannot reduce the influence of harmful errors through cell division. As a result, protein misfolding embodies a central role in several major neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, ALS, and other rare prion diseases, This review explores the molecular pathways that guide protein folding, the factors that lead into protein misfolding, and the effects of misfolded protein accumulation, while also examining real world diagnostic and therapeutic strategies in restricting protein misfolding.

Protein Folding Fundamentals

Protein folding is directed by the chemical properties of amino acids, but intracellular conditions are shown to sensitively impact folding within a cell through experimental trials. Fluorescence based folding assays indicate that molecular chaperones such as Hsp70 and Hsp90 stabilize correct folding outcomes by over 30% in crowded cell environments, effectively highlighting their role as assistants for folding intermediates to ensure the protein folding is carried out smoothly (Chiti & Dobson, 2017). Structural analyses using cryo electron microscopy further demonstrates how the properly folded proteins submerse hydrophobic residues within the protein. In contrast, when a protein misfolds, the intermediates along with the chaperones expose such residues, leading to monomers creating more complex structures through nucleation-dependent aggregation. As shown in Figure 1, proteins can follow multiple folding trajectories, including off-pathway intermediates that increase aggregation risk.



Figure 1. Protein folding pathways showing transitions from unfolded and partially folded states to native conformations or misfolded aggregates. Adapted from Chiti & Dobson (2017).

The ubiquitin proteasome system represents an additional layer of protection for the cell by targeting and degrading misfolded proteins. Proteasome activity measurements show that the ubiquitin tagged proteins are removed noticeably faster than proteins that weren't tagged, highlighting the efficiency of the quality control pathway, one of the molecular pathways that determine appropriate protein folding (Ciechanover & Kwon, 2013). However, when chaperone or proteasome activity starts to dramatically increase, the degradation process is put on a halt, allowing misfolded proteins to begin accumulating and increase the likelihood of aggregate formation and cellular toxicity.

Mechanisms of Protein Misfolding

Protein misfolding stems from sequenced based vulnerabilities and cellular stressors. Thermal denaturation assays express that even a single amino acid substitution can destabilize the protein by 2 to 5 degrees Celsius, which represents a shift in the equilibrium towards partially folding or misfolded protein states (Knowles et al., 2014). These destabilized states can expose the hydrophobic patches that have already been shown to promote aggregation if exposed. Additionally, oxidative stress can further catalyze the misfolding reaction. Vitro oxidation experiments show that modification of methionine and cysteine residues increases aggregation rates 2 or 3 times the original rate, illustrating how oxygen can react with proteins in ways that disrupt normal folding pathways. As shown in Figure 2, the amyloid state becomes thermodynamically favorable under destabilizing conditions, helping explain why misfolded proteins transition toward aggregation.



Figure 2. Thermodynamic relationship between native and amyloid states, showing the free-energy barrier (ΔG) and how amyloid fibrils become increasingly stable as chain length increases. Adapted from Knowles, Vendruscolo & Dobson (2014).

Rapid accumulation of such misfolded proteins activates the unfolded protein response (UPR), a signaling network that works to restore homeostasis in the endoplasmic reticulum. Assays show that a controlled UPR activation can reduce the global misfolded protein synthesis while simultaneously increasing the amount of chaperone expression. However, delayed activation heavily correlates with higher rates of apoptosis, highlighting the balance between adaptive and destructive stress signaling (Hetz & Saxena, 2017). As more proteins start to misfold, the misfolded proteins start to self aggregate into insoluble amyloid fibrils. Further studies over kinetic aggregation reveal that oligomers begin to form rapidly and are central drivers of early disease progression that form into amyloid fibrils. These amyloid fibrils are the basis for many of the diseases in this paper, like Parkinson's disease and other prion diseases.

Pathological Consequences of Misfolding

Misfolded proteins disrupt essential cellular processes across various pathways. In neuronal cultures, exposure to Aβ oligomers noticeably reduces synaptic signaling output by about 40%, exemplifying how early aggregation species can directly impair communication between neurons (Selkoe & Hardy, 2016). Additionally, mitochondrial function also gets compromised. Measurements of mitochondrial membranes show significant structural declines following exposure to misfolded SOD1 or α-synuclein, heavily indicating reduced ATP production and increased oxidative stress. As illustrated in Figure 3, misfolded proteins contribute to mitochondrial dysfunction through oxidative stress, mtDNA disruption, and impaired energy production.



Figure 3. Mitochondrial dysfunction in Alzheimer's disease, illustrating how oxidative stress, mtDNA damage, impaired biogenesis, and Aβ interactions contribute to reduced ATP production and cellular stress. Adapted from Al-Zubaidi et al., 2023 (Biochemical Pharmacology).

Additional calcium imaging experiments show that oligomeric aggregates disrupt homeostasis among ions, and that leads to elevated intracellular calcium levels that intensify cellular stress. Moreover, these misfolded proteins also activate microglia and astrocytes, and other inflammatory marker assays prove that there is increased cytokine production in regions with high aggregate buildup (Lashuel, 2020). Over time, these combined effects drive progressive neural dysfunction and cell death via apoptosis, leading to the neurodegeneration that is seen in ALS, Parkinson's, Alzheimer's, and other prion diseases.

Disease Case Studies

Alzheimer's disease is characterized by the misfolding of both Aβ and tau proteins. Electrophysiology studies express that Aβ oligomers at concentrations of 5 to 10 μM reduce hippocampal synaptic transmission by approximately 40%, expressing the impact on early cognitive decline (Selkoe & Hardy, 2016). Tau misfolding further contributes to the early cognitive decline, as further biochemical assays reveal up to a 50% reduction in microtubule stability in regions with high tau abundance, indicating impaired axonal transport. Imaging studies show that misfolded tau spreads in a prion-like manner, with affected regions exhibiting structural deterioration.

Parkinson's disease focuses on the misfolding of α-synuclein, a small protein that's primarily located at the presynaptic terminals and is essential for regulated brain activity. Cell based aggregation assays show that α-synuclein oligomers impair synaptic vesicle recycling, thereby reducing neurotransmitter release efficiency (Lashuel, 2020). Postmortem analyses reveal that dense Lewy bodies are composed of misfolded α-synuclein, and further biochemical studies go on to indicate that these aggregates interfere with mitochondrial function, inhibiting dopaminergic neuron function.

ALS involves misfolding of proteins such as TDP-43, SOD1, and FUS. Cytoplasmic aggregates of misfolded TDP-43 disrupt RNA processing, with affected neurons showing substantial reductions in normal nuclear TDP-43 levels (Taylor et al., 2003). Mutant SOD1 loses

its antioxidant function, and oxidative stress assays reveal increased reactive oxygen species in cells expressing misfolded SOD1. These disruptions contribute to motor neuron degeneration and progressive paralysis.

Prion diseases are driven by templated misfolding. RT-QuIC assays demonstrate that misfolded prion protein (PrPSc) can seed misfolding of normal prion protein (PrPC) with diagnostic accuracy exceeding 90% (Soto, 2009). Animal studies show rapid disease progression following exposure to PrPSc, highlighting the unique transmissibility of prion disorders.

Proteostasis and Cellular Defense Systems

Proteostasis systems in the human body generally decline with age, which increases the body's vulnerability to the potential consequences of protein misfolding accumulation. Proteasome activity assays determined that a 20 to 30% reduction in degradation efficiency in aged neurons, emphasizing how the misfolded proteins still persist against the proteostasis systems (Ciechanover & Kwon, 2013). Autophagic flux measurements show that impaired autophagy correlates with a higher aggregate burden in different neurodegenerative disease models. Furthermore, UPR activation studies indicate that chronic ER stress leads to increased cell self destruction, or apoptosis, emphasizing the importance of a balanced and strong proteostasis signaling system (Hetz & Saxena, 2017). Collectively, these findings illustrate how aging paired with formed aggregates can weaken cells' ability to maintain protein homeostasis.

Diagnostic Approaches

Modern diagnostic tools heavily rely on experimental validation. PET imaging studies using amyloid binding tracers have reported sensitivities as high as 85%, allowing different clinicians to visualize plaque distribution in patients (Walsh et al., 2022). Similarly, cryo electron microscopy provides atomic level resolution of amyloid fibrils that allow clinicians to understand structural reconstructions (Eisenberg & Sawaya, 2017). RT-QuIC assays for prion diseases demonstrate diagnostic accuracy exceeding 90%, making them one of the most reliable tools for detecting misfolded prion proteins (Soto, 2009). These technologies collectively enable earlier and more precise detection of misfolding-related disorders.

Therapeutic Strategies

Therapeutic strategies increasingly target the molecular mechanisms underlying misfolding. Clinical trials of Aβ-targeting antibodies report reductions in plaque burden of 20–30% after sustained treatment, demonstrating enhanced clearance of misfolded proteins (Walsh et al., 2022). Small molecule stabilizers increase protein stability by several degrees Celsius in thermal denaturation assays, reducing misfolding risk (Chiti & Dobson, 2017). Gene therapy approaches targeting mutant proteins show knockdown efficiencies of 40 to 60%, offering potential for long-term correction (Jumper et al., 2021). Proteostasis enhancing drugs also demonstrate increased autophagic flux in cell models, supporting their role in aggregate clearance.

Emerging Technologies and Future Directions

Artificial intelligence tools such as AlphaFold have demonstrated remarkable accuracy in predicting protein structures, achieving average RMSD values within 1 Å of experimentally determined structures (Jumper et al., 2021). Cryo-electron microscopy continues to advance, with recent studies resolving amyloid fibrils at near-atomic resolution. Personalized medicine approaches are being explored, and early trials suggest that patient-specific protein profiles may guide targeted therapeutic strategies. Synthetic chaperones and engineered enzymes represent emerging possibilities for directly removing toxic aggregates, offering new pathways for intervention.

Future Experimental Pathways

These micro-intermediates can be predicted using computer simulations and tested in the lab through a combined process that merges enhanced-sampling structure prediction with quick-capture biophysics and independent verification. To do this, first create a group of candidate micro-intermediates by starting with AlphaFold as the model. Then, use enhanced-sampling techniques to explore non-native conformations. Next, set up a time-resolved experimental capture workflow that links stopped-flow hydrophobicity probes, millisecond single-molecule FRET, and microfluidic spray vitrification for preparing cryo-EM grids at different time points (Eisenberg & Sawaya, 2017). Assess seeding ability and cellular toxicity by testing the captured species in cell-free aggregation assays and in primary neuronal cultures with synaptic physiology, mitochondrial tests, and calcium imaging. Convert validated intermediates into conformation-specific agents for use in refined RT-QuIC assays and PET tracer development, allowing for in vivo detection and stratification. Include strict controls, such as mutations expected to destabilize micro-intermediates and known seeding and non-seeding species, as well as independent validation methods like HDX-MS and cross-linking mass spectrometry. Define success as the reliable capture of at least one predicted micro-intermediate, showing that it promotes oligomerization more effectively than native or fully unfolded states, and providing evidence that targeting the intermediate lowers seeding or toxicity in cellular or animal models. The pipeline has known challenges, including prediction uncertainty for intrinsically disordered regions, possible bias in rapid-capture methods favoring longer-lived species, and gaps between in vitro results and human disease.

Bibliography

Chiti, F., & Dobson, C. M. (2017). Protein misfolding, amyloid formation, and human disease. *Annual Review of Biochemistry, 86*, 27–68. https://www.annualreviews.org/content/journals/10.1146/annurev-biochem-061516-045115

Ciechanover, A., & Kwon, Y. T. (2013). Degradation of misfolded proteins in neurodegenerative diseases. *Cold Spring Harbor Perspectives in Biology, 5*(9), a017863. https://pmc.ncbi.nlm.nih.gov/articles/PMC3571097/

Eisenberg, D., & Sawaya, M. R. (2017). Structural studies of amyloid fibrils. *Annual Review of Biochemistry, 86*, 69–95. https://www.annualreviews.org/content/journals/10.1146/annurev-biochem-061516-045104

Hetz, C., & Saxena, S. (2017). ER stress and the unfolded protein response in neurodegeneration. *Nature Reviews Neurology, 13*(8), 477–491. https://www.nature.com/articles/nrneurol.2017.99

Jumper, J., Evans, R., Pritzel, A., et al. (2021). Highly accurate protein structure prediction with AlphaFold. *Nature, 596*(7873), 583–589. https://www.nature.com/articles/s41586-021-03819-2

Knowles, T. P. J., Vendruscolo, M., & Dobson, C. M. (2014). The amyloid state and its association with protein misfolding diseases. *Nature Reviews Molecular Cell Biology, 15*(6), 384–396. https://williams.chemistry.gatech.edu/course_Information/6572_fall_2021/papers/Knowles_2014_amyloids.pdf

Selkoe, D. J., & Hardy, J. (2016). The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Molecular Medicine, 8*(6), 595–608. https://link.springer.com/article/10.15252/emmm.201606210

Soto, C. (2009). Unfolding the role of protein misfolding in neurodegenerative diseases. *Nature Reviews Neuroscience, 10*(6), 387–399. https://pmc.ncbi.nlm.nih.gov/articles/PMC2674794/

Taylor, J. P., Hardy, J., & Fischbeck, K. H. (2003). Toxic proteins in neurodegenerative disease. *Nature Reviews Neuroscience, 4*(1), 49–58. https://www.researchgate.net/publication/11308406_Toxic_Proteins_in_Neurodegenerative_Disease

Walsh, D. M., Selkoe, D. J., & Holtzman, D. M. (2022). Amyloid-targeting antibodies in Alzheimer's disease: Mechanisms and clinical outcomes. *Nature Reviews Drug Discovery, 21*(9), 628–644. https://pmc.ncbi.nlm.nih.gov/articles/PMC12470750/

Lashuel, H. A. (2020). Alpha-synuclein and the pathogenesis of Parkinson's disease. *Biochemical Pharmacology, 180*, 114162.

https://www.sciencedirect.com/science/article/pii/S0969996120301510?via%3Dihub

Spillantini, M. G., & Goedert, M. (2024). Tau pathology and neurodegeneration: New insights. *Molecular Neurodegeneration, 19*, 29. https://link.springer.com/article/10.1186/s40035-024-00429-6